Original news and analysis on international IP policy
An article in the newly launched Journal of Health Diplomacy about the stalled progress at the World Health Organization for a medical research and development (R&D) convention discusses systemic failures in global health policy.
The latest instalment of the World Intellectual Property Organization seminar series titled “The Economics of Intellectual Property” covered the issue of product patents in the pharmaceutical industry. Discussion focussed on the economics of intellectual property rights and how pharmaceutical patent protection might not be the sole culprit in the access to innovation problem.
Prices of cancer drugs must be lowered to be affordable for patients and to maintain sound long-term healthcare policies, according to a group of chronic myeloid leukemia (CML) experts in a recent Blood journal editorial.
The United States Supreme Court came to a decision yesterday on the case of Association for Molecular Pathology v. Myriad Genetics, Inc., striking down Myriad’s patent on isolating human genes from the bloodstream.
The World Health Organization (WHO) has released an updated guidance document on pandemic influenza risk management, which includes the Pandemic Influenza Preparedness (PIP) Framework for the sharing of influenza viruses and access to vaccines and other benefits that was discussed by member states during the 66th World Health Assembly (WHA) in May.
A recent Geneva-based study found that so-called evergreening practices utilised by drug manufacturers are successful in protecting profits by maintaining company market share and offsetting generic competition and cost containment policies.
Thirteen years after publication of the landmark report, “Tobacco Company Strategies to Undermine Tobacco Control Activities at the World Health Organization,” little has changed and industry manipulations continue, one of the lead authors has said.
Lower-income countries receive much less attention in terms of clinical trial research, according to a study published in this month’s World Health Organization (WHO) Bulletin. The study also underscored the value and importance the WHO International Clinical Trials Registry Platform (ICTRP) provides as a resource for evaluating the distribution of clinical trials around the world, and for providing information for future policy on health R&D.
A US report released this week found that the President’s Emergency Plan for AIDS Relief (PEPFAR) has helped to make antiretroviral drug supply chains more efficient and reliable, but still contains several weaknesses that need to be addressed.
Wrapping up one day early, the 66th World Health Assembly adopted a range of public health resolutions and decisions, some with key intellectual property implications, including a decision to convene a technical meeting on new public health R&D projects, a compromise on advancing the poor quality medicines mechanism, and resolutions on both neglected tropical diseases and noncommunicable diseases. Importantly, the novel coronavirus situation drew attention to WHO’s progress in pandemic influenza preparedness.
The issue of access to medicines is on the agenda at this week’s World Health Assembly (WHA) and public health advocates are seeking greater clarity and detail about the latest member state effort to address failings in the global system of research and development for medical products.
Members of the World Health Organization this week have made noncommunicable diseases a top priority, and work on a draft resolution and action plan is being carried out by a drafting group that will report back later in the week.